CA2761571A1 - Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy - Google Patents

Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy Download PDF

Info

Publication number
CA2761571A1
CA2761571A1 CA2761571A CA2761571A CA2761571A1 CA 2761571 A1 CA2761571 A1 CA 2761571A1 CA 2761571 A CA2761571 A CA 2761571A CA 2761571 A CA2761571 A CA 2761571A CA 2761571 A1 CA2761571 A1 CA 2761571A1
Authority
CA
Canada
Prior art keywords
subject
expression
biomarker
biomarkers
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2761571A
Other languages
English (en)
French (fr)
Inventor
Ming-Sound Tsao
Frances A. Shepherd
Igor Jurisica
Sandy D. Der
Chang-qi ZHU
Dan Strumpf
Lesley Seymour
Keyue Ding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of CA2761571A1 publication Critical patent/CA2761571A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Software Systems (AREA)
  • Urology & Nephrology (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
CA2761571A 2008-05-14 2009-05-14 Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy Abandoned CA2761571A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7172808P 2008-05-14 2008-05-14
US61/071,728 2008-05-14
PCT/CA2009/000650 WO2009137921A1 (en) 2008-05-14 2009-05-14 Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy

Publications (1)

Publication Number Publication Date
CA2761571A1 true CA2761571A1 (en) 2009-11-19

Family

ID=41318311

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2761571A Abandoned CA2761571A1 (en) 2008-05-14 2009-05-14 Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy

Country Status (6)

Country Link
US (3) US8211643B2 (cg-RX-API-DMAC10.html)
EP (1) EP2288741B1 (cg-RX-API-DMAC10.html)
JP (1) JP5583117B2 (cg-RX-API-DMAC10.html)
AU (1) AU2009246009A1 (cg-RX-API-DMAC10.html)
CA (1) CA2761571A1 (cg-RX-API-DMAC10.html)
WO (1) WO2009137921A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009246009A1 (en) 2008-05-14 2009-11-19 University Health Network Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US20100184063A1 (en) * 2008-05-14 2010-07-22 Ming-Sound Tsao Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US20110238322A1 (en) * 2008-11-03 2011-09-29 Precision Therapeutics, Inc. Methods of simulating chemotherapy for a patient
CN101705306B (zh) * 2009-12-01 2012-07-11 华中农业大学 应用as-pcr检测牛尿苷酸合酶缺乏症的方法
US9607202B2 (en) 2009-12-17 2017-03-28 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of generating trophectoderm and neurectoderm from human embryonic stem cells
EP2582848A4 (en) * 2010-06-18 2013-12-04 Med Biogene Inc PROGNOSTIC AND PREDICTIVE GENETIC SIGNATURE FOR LARGE CELL LUNG CANCER AND ADJUVANT CHEMOTHERAPY
US9200325B2 (en) * 2011-04-01 2015-12-01 Indiana University Research And Technology Corporation Diagnostic methods and kit for detecting cancer
JP2014516531A (ja) * 2011-05-25 2014-07-17 ノバルティス アーゲー 肺癌に対するバイオマーカー
CA2843887A1 (en) * 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
US20150352193A1 (en) 2013-01-18 2015-12-10 Ellis Kline Selective glycosidase regimen for immune programming and treatment of cancer
US10386370B2 (en) 2013-02-11 2019-08-20 Incuron, Inc. Use of facilitates chromatin transcription complex (FACT) in cancer
US11021752B2 (en) 2013-03-15 2021-06-01 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
KR101830700B1 (ko) * 2013-11-11 2018-02-21 주식회사 파나진 클램핑 프로브 및 검출 프로브를 이용한 다중 표적핵산 검출방법
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
EP3164508B1 (en) 2014-07-02 2023-06-07 Myriad myPath, LLC Genes and gene signatures for diagnosis and treatment of melanoma
WO2016047688A1 (ja) * 2014-09-24 2016-03-31 国立研究開発法人国立がん研究センター 扁平上皮がんに対する化学放射線療法の有効性を評価するための方法
WO2016050623A1 (en) * 2014-09-29 2016-04-07 Institut Gustave Roussy Prognosis markers in lung cancer
CN106755309A (zh) * 2016-11-18 2017-05-31 北京致成生物医学科技有限公司 分子标记物在制备胰腺癌预后评估产品中的应用
JP7106810B2 (ja) * 2018-04-19 2022-07-27 学校法人 埼玉医科大学 新規肺がんマーカー
CN108949997A (zh) * 2018-08-24 2018-12-07 南京求臻基因科技有限公司 一种肺癌检测标志物及诊断试剂盒
CN109859801B (zh) * 2019-02-14 2023-09-19 辽宁省肿瘤医院 一种含有七个基因作为生物标志物预测肺鳞癌预后的模型及建立方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
JP2005503145A (ja) 2001-08-16 2005-02-03 ザ ユナイテッド ステイツ オブ アメリカ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 非小細胞肺癌の分子特性
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US20100184063A1 (en) * 2008-05-14 2010-07-22 Ming-Sound Tsao Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
AU2009246009A1 (en) 2008-05-14 2009-11-19 University Health Network Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy

Also Published As

Publication number Publication date
JP5583117B2 (ja) 2014-09-03
EP2288741B1 (en) 2015-01-28
US20090291448A1 (en) 2009-11-26
US8211643B2 (en) 2012-07-03
WO2009137921A1 (en) 2009-11-19
US20160024596A1 (en) 2016-01-28
JP2011523549A (ja) 2011-08-18
AU2009246009A1 (en) 2009-11-19
US20120323594A1 (en) 2012-12-20
EP2288741A4 (en) 2011-08-24
EP2288741A1 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
US8211643B2 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US20160032407A1 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
JP5745848B2 (ja) 胃腸癌での増殖の徴候及び予後
US20120258878A1 (en) Prognostic gene signatures for non-small cell lung cancer
JP6404304B2 (ja) メラノーマ癌の予後予測
Childs et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma
WO2012066451A1 (en) Prognostic and predictive gene signature for colon cancer
WO2014071279A2 (en) Gene fusions and alternatively spliced junctions associated with breast cancer
CA2714521A1 (en) Susceptibility variants for lung cancer
CA2928901A1 (en) Cancer biomarkers and classifiers and uses thereof
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
US20140315935A1 (en) Gene signatures for lung cancer prognosis and therapy selection
Hwang et al. Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer
Zhang et al. Dysregulation of DNA methylation patterns may identify patients with breast cancer resistant to endocrine therapy: A predictive classifier based on differentially methylated regions
Low et al. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer
WO2023196978A2 (en) Myc program as a marker of response to enzalutamide in prostate
US20120077687A1 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
Zhang et al. Long non-coding RNA signature for predicting gastric cancer survival based on genomic instability
Buechler et al. EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor–Positive Breast Cancer
JP2008529554A (ja) 固形腫瘍の予後のための薬理ゲノミクス的マーカー
WO2010045346A1 (en) Expression analysis of coronary artery atherosclerosis
Du et al. A seven-autophagy-related long non-coding RNA signature can accurately predict the prognosis of patients with renal cell carcinoma
US20160281177A1 (en) Gene signatures for renal cancer prognosis
US20120100999A1 (en) Prognostic gene expression signature for squamous cell carcinoma of the lung

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140429

FZDE Discontinued

Effective date: 20191010